Latest Articles

Publication Date
Merck Announces Positive Phase 3 Results for Endometrial Cancer Drug - HarianBasis.co

Merck Announces Positive Phase 3 Results for Endometrial Cancer Drug HarianBasis.co

Published: May 23, 2026, 1:10 p.m.
MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial - MSN

MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial MSN

Published: May 23, 2026, 12:41 p.m.
Merck (MRK) Phase 3 TroFuse-005 Trial for Endometrial Cancer Meets Primary Endpoints - Yahoo Finance

Merck (MRK) Phase 3 TroFuse-005 Trial for Endometrial Cancer Meets Primary Endpoints Yahoo Finance

Published: May 23, 2026, 12:01 p.m.
Decidualization potential of endometrial mesenchymal stem cells and their role in reproductive health.

The establishment of a successful pregnancy depends on proper embryo development and coordinated endometrial differentiation, particularly through the process of decidualization. Mesenchymal stem/stromal cells (MSCs), especially those derived from endometrial …

Published: May 23, 2026, midnight
Lesion-centric reprogramming: hydrogel-enabled photothermal reset of endometriosis pain.

Endometriosis-associated pelvic pain represents a prototypical failure of systemic therapy for a locally organized, neuroinflammatory disease. Persistent pain arises from the convergence of estrogen-driven lesion survival, chronic inflammation, fibrosis, and …

Published: May 23, 2026, midnight
Endometrial Serous Carcinoma Arising From Adenomyosis - Cureus

Endometrial Serous Carcinoma Arising From Adenomyosis Cureus

Published: May 22, 2026, 4:43 p.m.
Advances in Molecular Profiling and GLP-1 Therapy Offer Hope in Endometrial Cancer - Pharmacy Times

Advances in Molecular Profiling and GLP-1 Therapy Offer Hope in Endometrial Cancer Pharmacy Times

Published: May 22, 2026, 4:14 p.m.
Can GLP-1 Receptor Agonists Improve Outcomes in Patients at Risk for Endometrial Cancer? - Pharmacy Times

Can GLP-1 Receptor Agonists Improve Outcomes in Patients at Risk for Endometrial Cancer? Pharmacy Times

Published: May 22, 2026, 4:29 a.m.
Dostarlimab Combo Shows Durable Disease Control in dMMR/MSI-H Endometrial Cancer, Full Data Due at ASCO 2026 - OncLive

Dostarlimab Combo Shows Durable Disease Control in dMMR/MSI-H Endometrial Cancer, Full Data Due at ASCO 2026 OncLive

Published: May 22, 2026, 3:43 a.m.
Antagonizing the corticotropin-releasing hormone receptor 1 with an orally bioavailable drug reduces endometriosis pain and associated adhesions†.

Estrogen stimulates corticotropin-releasing hormone (CRH) expression in endometrial tissue, and CRH signaling contributes to inflammation and pain, suggesting a mechanistic role in endometriosis pathophysiology. We previously identified elevated CRH receptor-1 …

Published: May 22, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!